Hyku

About:

Hyku is a biotech company that develops precise covalent targeting of disease-causing proteins.

Website: https://www.hykubiosciences.com

Top Investors: RA Capital Management, KB Investment, Novartis Venture Fund, Droia Ventures, The Mark Foundation for Cancer Research

Description:

Hyku is a biotech company that develops precise covalent targeting of disease-causing proteins. The Hyku platform identifies molecules that covalently bind non-cysteine amino acids to aid in the creation of innovative medicines that can address present issues with a variety of disease targets, such as selectivity, druggability, and resistance.